BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11313681)

  • 21. Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages.
    Shaw PJ; Nath C; Berry A; Earl JW
    Bone Marrow Transplant; 2004 Aug; 34(3):197-205. PubMed ID: 15195074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.
    Madden T; de Lima M; Thapar N; Nguyen J; Roberson S; Couriel D; Pierre B; Shpall EJ; Jones RB; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):56-64. PubMed ID: 17222753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
    Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
    Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring of Busulphan Concentrations in Children Undergone Hematopoietic Stem Cell Transplantation: Unicentric Experience over 10 years.
    Faraci M; Tinelli C; Lanino E; Giardino S; Leoni M; Ferretti M; Castagnola E; Broglia M; De Silvestri A; Di Martino D; Bartoli A
    Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):173-181. PubMed ID: 28801891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation.
    Matthews RH; Emami M; Connaghan DG; Holland HK; Morris LE
    Bone Marrow Transplant; 2007 Apr; 39(7):397-400. PubMed ID: 17322933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen.
    Beri R; Chunduri S; Sweiss K; Peace DJ; Mactal-Haaf C; Dobogai LC; Shord S; Quigley JG; Chen YH; Mahmud N; Rondelli D
    Bone Marrow Transplant; 2010 Feb; 45(2):249-53. PubMed ID: 19543331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications.
    Beelen DW; Trenschel R; Casper J; Freund M; Hilger RA; Scheulen ME; Basara N; Fauser AA; Hertenstein B; Mylius HA; Baumgart J; Pichlmeier U; Hahn JR; Holler E
    Bone Marrow Transplant; 2005 Feb; 35(3):233-41. PubMed ID: 15592494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage.
    Clopés A; Sureda A; Sierra J; Queraltó JM; Broto A; Farré R; Moreno E; Brunet S; Martino R; Mangues MA
    Eur J Haematol; 2006 Jul; 77(1):1-6. PubMed ID: 16573745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective appraisal of busulfan dose adjustment in children.
    Dupuis LL; Najdova M; Saunders EF
    Bone Marrow Transplant; 2000 Dec; 26(11):1143-7. PubMed ID: 11149723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation.
    Schuler US; Ehrsam M; Schneider A; Schmidt H; Deeg J; Ehninger G
    Bone Marrow Transplant; 1998 Aug; 22(3):241-4. PubMed ID: 9720736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
    Dupuis LL; Sibbald C; Schechter T; Ansari M; Gassas A; Théorêt Y; Kassir N; Champagne MA; Doyle J
    Biol Blood Marrow Transplant; 2008 May; 14(5):576-82. PubMed ID: 18410900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation.
    Poonkuzhali B; Srivastava A; Quernin MH; Dennison D; Aigrain EJ; Kanagasabapathy AS; Krishnamoorthy R; Chandy M
    Bone Marrow Transplant; 1999 Jul; 24(1):5-11. PubMed ID: 10435727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
    Vassal G; Michel G; Espérou H; Gentet JC; Valteau-Couanet D; Doz F; Mechinaud F; Galambrun C; Neven B; Zouabi H; Nguyen L; Puozzo C
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):113-23. PubMed ID: 17393167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation.
    Ritchie DS; Szer J; Roberts AW; Shuttleworth P; Grigg AP
    Bone Marrow Transplant; 2002 Nov; 30(10):645-50. PubMed ID: 12420202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
    Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant.
    Tse WT; Duerst R; Schneiderman J; Chaudhury S; Jacobsohn D; Kletzel M
    Bone Marrow Transplant; 2009 Aug; 44(3):145-56. PubMed ID: 19182832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation.
    Ryu SG; Lee JH; Choi SJ; Lee JH; Lee YS; Seol M; Hur EH; Lee SH; Bae KS; Noh GJ; Lee MS; Yun SC; Han SB; Lee KH
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1095-105. PubMed ID: 17697972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
    Aggarwal C; Gupta S; Vaughan WP; Saylors GB; Salzman DE; Katz RO; Nance AG; Tilden AB; Carabasi MH
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):770-7. PubMed ID: 16785066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients.
    Malär R; Sjöö F; Rentsch K; Hassan M; Güngör T
    Pediatr Transplant; 2011 Sep; 15(6):580-8. PubMed ID: 21736681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation.
    Bartelink IH; Bredius RG; Belitser SV; Suttorp MM; Bierings M; Knibbe CA; Egeler M; Lankester AC; Egberts AC; Zwaveling J; Boelens JJ
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):231-41. PubMed ID: 19167683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.